Arrowhead plummets on FDA partial hold
This article was originally published in Scrip
Executive Summary
Shares of biotech Arrowhead Research plunged 28% on 12 January after the company disclosed the FDA had imposed a partial clinical hold on a trial of the firm's chronic hepatitis B infection drug ARC-520.
You may also be interested in...
Arrowhead Tumbles As FDA Puts A Clinical Hold On Novel HBV Therapy Trial
Shares in US biotech Arrowhead Pharmaceuticals took a tumble after the FDA put a clinical hold on one of its small interfering RNAs (siRNAs) Phase II programs in hepatitis B because of concerns over a delivery vehicle that is also used in two of its other Phase II candidates.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.